TELA News and Press, TELA Bio Inc. From 11/13/21

TELA Bio, Inc. (TELA) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Hannah Jeffrey - The Gilmartin Group Tony Koblish - President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants An...

Image source: The Motley Fool. TELA Bio, Inc. (NASDAQ: TELA) Q3 2021 Earnings Call Nov 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: TELA Bio, Inc. (TELA) Q3 2021 Earnings Call Transcript

TELA Bio (NASDAQ:TELA): Q3 net loss was $8.3 million Revenue of $7.65M (+44.1% Y/Y) beats by $0.11M. Press Release Financial Outlook We continue to monitor and evaluate the impact the COVID-19 pandemic has had and will continue to have on our results of operations. Despite these challenges, f...

MALVERN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reporte...

12-month follow-up data in 75 patients treated with OviTex ® Reinforced Tissue Matrix (RTM) for ventral hernia repair demonstrates an overall hernia recurrence rate of 2.7%. Final 24-month analysis shows hernia recurrence rate remains below 5%. MALVERN, ...

MALVERN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Com...

Today, we peek in on TELA Bio for the first time. The company has a couple of products on the market that should take market share in their niches. A full investment analysis follows in the paragraphs below. For further details see: Our First Look At TELA Bio

TELA Bio (NASDAQ:TELA) has entered into an exclusive distribution agreement with Next Science for the advanced anti-biofilm surgical wash. The company plans to commence private label marketing of the solution for plastic surgery in early 2022. Additionally, TELA Bio received a first righ...

MALVERN, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced it has enter...

MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the com...